Document:

<PAGE>
                                                                   EXHIBIT 10.10

                         EXCLUSIVE SUBLICENSE AGREEMENT
                        Re: UNMC Docket Nos. 63095 series

This Agreement having the effective date of October 10, 2003 ("EFFECTIVE DATE")
is made between UNEMED Corporation, 986099 Nebraska Medical Center, Omaha,
Nebraska 68198-6099 ("UNEMED") and ImaRx Therapeutics, Incorporated, 1635 East
18th Street, Tucson, AZ 85719 ("LICENSEE").

WHEREAS, the University of Nebraska Medical Center ("UNMC") desires to license
and otherwise commercialize certain technology resulting from the research of
its faculty; and

WHEREAS, UNEMED is a biomedical technology development company charged with and
having authority to assist UNMC in the licensing and commercial development of
its technology; and

WHEREAS, ImaRx Therapeutics, Incorporated is desirous of licensing certain UNMC
technology with the intent of furthering its commercial development;

In consideration of the mutual promises and covenants set forth below, the
parties hereto agree as follows:

                                    ARTICLE I

                                   DEFINITIONS

As used in this Agreement, the following terms shall have the following
meanings:

1.1 AFFILIATE: any company, corporation, or business in which LICENSEE owns or
controls at least fifty percent (50%) of the voting stock or other ownership.
Unless otherwise specified, the term LICENSEE includes AFFILIATES.

1.2 FIELD: Therapeutic applications of Non-PESDA (Non-perfluorocarbon enhanced
sonicated dextrose albumin) microbubbles for the treatment of thrombosis, as
described in UNMC Docket Series 63095.

1.3 UNEMED: UNEMED Corporation, a for-profit Nebraska corporation having offices
at 701 S. 42nd Street, 986099 Nebraska Medical Center, Omaha, Nebraska,
69198-6099.

1.4 LICENSED PROCESSES: the processes covered by issued claims of PATENT RIGHTS,
on a country-by-country basis, that if made used, sold, imported or offered for
sale would constitute, but for the license granted to Company pursuant to this
Agreement, an infringement of a claim of PATENT RIGHTS (infringement shall
include, but is not limited to, direct, contributory, or inducement to
infringe).

<PAGE>

1.5 LICENSED PRODUCTS: products covered by issued claims of PATENT RIGHTS , on a
country-by-country basis, that if made, used, sold, imported or offered for sale
would constitute, but for the license granted to Company pursuant to this
Agreement, an infringement of a claim of PATENT RIGHTS (infringement shall
include, but is not limited to, direct, contributory, or inducement to
infringe).

1.6 LICENSEE: ImaRx Therapeutics, 1635 East 18th Street, Tucson, AZ 85719

1.7 NET SALES: the amount billed, invoiced, or received (whichever occurs first)
for sales, leases, or other transfers of LICENSED PRODUCTS, less:

     (a) customary trade, quantity or cash discounts and non-affiliated brokers'
or agents' commissions actually allowed and taken;

     (b) amounts repaid or credited by reason of rejection or return;

     (c) to the extent separately stated on purchase orders, invoices, or other
documents of sale, taxes levied on and/or other governmental charges made as to
production, sale, transportation, delivery or use and paid by or on behalf of
LICENSEE or sublicensees; and

     (d) reasonable charges for delivery or transportation or insurance provided
by third parties, if separately stated.

     NET SALES also includes the fair market value of any non-cash consideration
received by LICENSEE or sublicensees (other than research and development
payments as set forth in 4.2(a)) for the sale, lease, or transfer of LICENSED
PRODUCTS.

1.8 NON-COMMERCIAL RESEARCH PURPOSES: use of PATENT RIGHTS for non-commercial
academic research or other non-commercial scholarly purposes which are
undertaken at a non-profit or governmental institution; provided however that
such entity does not use the PATENT RIGHTS in the production or manufacture of
products for sale or the performance of services for a fee.

1.9 NON-ROYALTY SUBLICENSE INCOME: Sublicense issue fees, sublicense maintenance
fees, sublicense milestone payments, and similar non-royalty payments made by
sublicensees to LICENSEE on account of sublicenses pursuant to this Agreement.

1.10 PATENT RIGHTS:

Patent applications associated with Tech ID # 95009 (the entire 63095 Family)
Title: New Agent for the Treatment of Thrombosis

<TABLE>
<CAPTION>
                                                             Patent #
UNMC Docket #                                           Title (issue date)
-------------                                           ------------------
<S>             <C>                         <C>
63095                    5,648,098          Thrombolytic Agents and Methods of
                                            Treatment for Thrombosis (issued 7/15/97)

63095.1                  5,980,950          Thrombolytic Agents and Methods of
</TABLE>

<PAGE>

<TABLE>
<S>             <C>                         <C>
                (divisional of 63095)       Treatment for Thrombosis (issued 11/09/99)

63095.2                  6,197,345          Thrombolytic Agents and Methods of
                (continuation of 63095.1)   Treatment for Thrombosis (issued 3/06/01)

63095.3                  Filed              Thrombolytic Agents and Methods of
                (continuation of 63095.2)   Treatment for Thrombosis (pending)
</TABLE>

the inventions disclosed and claimed therein, divisional patent applications,
issued patents, CIP applications to the extent any new matter reads on claims of
a parent application, reissued and reexamined patents, all limited by FIELD to
be included within this agreement, and to the extent they are owned or
controlled by INSTITUTIONS, any and all foreign patents and patent applications
corresponding thereto.

1.11 TERRITORY: Worldwide

1.12 The terms "Public Law 96-517" and "Public Law 98-620" include all
amendments to those statutes.

1.13 The terms "sold" and "sell" include, without limitation, leases and other
transfers and similar transactions.

1.14 INSTITUTIONS: The Board of Regents of the University of Nebraska, a public
body corporate, doing business as the University of Nebraska Medical Center,
986099 Nebraska Medical Center, Omaha, Nebraska, USA, 68198-6099.

                                   ARTICLE II

                                 REPRESENTATIONS

2.1 INSTITUTIONS are owners by assignment from inventor(s) of their entire
right, title and interest in PATENT RIGHTS, in the foreign patent applications
corresponding thereto, and in the inventions claimed therein.

2.2 UNEMED has the authority from INSTITUTIONS to issue licenses under PATENT
RIGHTS. If for any reason UNEMED and INSTITUTIONS terminate their agreement
providing such authority, or UNEMED ceases to exist, this Agreement shall
automatically be reassigned to INSTITUTIONS.

2.3 UNEMED is committed to the policy that ideas or creative works produced at
INSTITUTIONS should be used for the greatest possible public benefit, and
believes that every reasonable incentive should be provided for the prompt
introduction of such ideas into public

<PAGE>

use, all in a manner consistent with the public interest.

2.4 LICENSEE is prepared and intends to use commercially reasonable efforts
develop the invention and to bring to market products, which are subject to this
Agreement.

2.5 LICENSEE is desirous of obtaining an exclusive license in the TERRITORY in
order to practice the above-referenced invention covered by PATENT RIGHTS in the
United States and in certain foreign countries, and to manufacture or have
manufactured, use, import, sell and have sold in the commercial market the
products made in accordance therewith, and UNEMED is desirous of granting such a
license to LICENSEE in accordance with the terms of this Agreement.

<PAGE>

                                   ARTICLE III

                                 GRANT OF RIGHTS

3.1 UNEMED hereby grants to LICENSEE and LICENSEE accepts, subject to the terms
and conditions hereof, in the TERRITORY and in the FIELD:

     an exclusive commercial license under PATENT RIGHTS,

     to research and develop, make and have made, to use and have used, to sell
and have sold, offer for sale and import the LICENSED PRODUCTS, and to practice
the LICENSED PROCESSES, for the life of the PATENT RIGHTS. Such licenses shall
include the right to grant sublicenses. In order to provide LICENSEE with
commercial exclusivity for so long as the license under PATENT RIGHTS remains
exclusive, UNEMED agrees that it will not grant licenses under PATENT RIGHTS to
others except as required by INSTITUTIONS' obligations in paragraph 3.2(a) or as
permitted in paragraph 3.2(b) .

3.2 The granting and exercise of this license is subject to the following
conditions:

     (a) U.S. Public Law 96-517, U.S. Public Law 98-620; if a subject invention;
the Memorandum of Agreement between the INSTITUTIONS and UNEMED dated March 31,
1998; the Technology Development Program Agreement dated November 27, 1991 .

     (b) UNEMED on behalf of INSTITUTIONS reserves the right to

          (i) make, have made, provide and use for UNEMED's and INSTITUTION'S
          NON COMMERCIAL RESEARCH PURPOSES the subject matter described and
          claimed in PATENT RIGHTS, including the ability to distribute any
          UNEMED- or INSTITUTION-owned materials within the PATENT RIGHTS for
          NON-COMMERCIAL RESEARCH PURPOSES as is customary in the academic
          community.

          (ii) grant to others licenses to use and develop the PATENT RIGHTS
          outside of the FIELD of this agreement.

     (c) LICENSEE shall use commercially reasonable efforts to effect
introduction of the LICENSED PRODUCTS or LICENSED PROCESS into the commercial
market as soon as

<PAGE>

practicable, consistent with sound and reasonable business practice and
judgment; thereafter, until the expiration of this Agreement, LICENSEE shall
endeavor to keep LICENSED PRODUCTS or LICENSED PROCESSES reasonably available to
the public. Licensee shall use commercially reasonable efforts to meet the
milestones outlined in Section 3.2 (c), (i)-(iii) described below:

          (i) within three (3) years from the EFFECTIVE DATE of this Agreement,
          LICENSEE shall file an IND with the US FDA for a LICENSED PRODUCT or
          LICENSED PROCESS.

          (ii) within four (4) years from the EFFECTIVE DATE of this agreement,
          LICENSEE shall commence studies in humans with a LICENSED PRODUCT or
          LICENSED PROCESS.

          (iii) within six (6) years from the EFFECTIVE DATE of this agreement,
          LICENSEE shall commence Phase II studies with a LICENSED PRODUCT or
          LICENSED PROCESS.

     (d) At any time after 3 years from the effective date of this Agreement,
UNEMED may terminate or render this license non-exclusive if, in UNEMED's
reasonable judgment, the Progress Reports furnished by LICENSEE do not
demonstrate that LICENSEE has satisfied one of the following:

          (i) has succeeded in meeting the milestones as presented in
          3.2(c)i-iii, or

          (ii) is engaged in research, development, manufacturing, marketing or
          sublicensing activity (which includes making sublicenses reasonably
          available) appropriate to achieving 3.2(d)i, or

          (iii) has put the licensed subject matter into commercial use in at
          least one country in the TERRITORY hereby licensed, directly or
          through a sublicense, and is keeping the license subject matter
          reasonably available to the public.

     (e) In all sublicenses granted by LICENSEE hereunder, LICENSEE shall
include a requirement that the sublicensee use its commercially reasonable
efforts to bring the subject matter of the sublicense into commercial use as
quickly as is reasonably possible. LICENSEE

<PAGE>

shall further provide in such sublicenses that such sublicenses are subject and
subordinate to the terms and conditions of this Agreement applicable to a
sublicense, except: (i) the sublicensee may not further sublicense; and (ii) the
rate of royalty on NET SALES paid by the sublicensee to the LICENSEE. Copies of
all sublicense agreements shall be provided promptly to UNEMED. LICENSEE may
redact confidential information from such sublicenses.

     (f) After clinical or other evidence, provided in writing by UNEMED, to
LICENSEE, reasonably demonstrates the practicality of a particular use of PATENT
RIGHTS, which is not being developed or commercialized by LICENSEE, LICENSEE
shall either provide UNEMED with a reasonable development plan and start
development or attempt to reasonably sublicense of the particular PATENT RIGHTS
to a third party. If within six (6) months of such notification by UNEMED,
LICENSEE has not initiated such development efforts or sublicensed that
particular use of PATENT RIGHTS, UNEMED may reduce the FIELD to the extent of
such particular use of PATENT RIGHTS, as described in such notice, of this
license for such particular use of PATENT RIGHTS. This Paragraph 3.2 (f) shall
not be applicable if LICENSEE reasonably demonstrates to UNEMED that
commercializing such LICENSED PRODUCT(S) or granting such a sublicense would
have a potentially adverse commercial effect upon marketing or sales of the
LICENSED PRODUCTS developed and being sold by LICENSEE.

     (g) A license in any other field of use in addition to the FIELD shall be
the subject of a separate agreement and shall require LICENSEE's submission of
evidence, satisfactory to UNEMED, demonstrating LICENSEE's willingness and
ability to develop and commercialize in such other field of use the kinds of
products or processes likely to be encompassed in such other field.

     (h) During the period of exclusivity of this license in the United States,
LICENSEE shall cause any LICENSED PRODUCT, if a subject invention, produced for
sale in the United States to be manufactured substantially in the United States.

3.3 All rights reserved to the United States Government and others under Public
Law 96-517, and Public Law 98-620, if a subject invention, shall remain and
shall in no way be affected by this Agreement.

<PAGE>

                                   ARTICLE IV

                                    ROYALTIES

4.1 LICENSEE shall pay to UNEMED a non-refundable license royalty fee in the sum
of ten thousand dollars ($10,000.00) upon execution of this Agreement.

4.2 (a) LICENSEE shall pay to UNEMED during the term of this Agreement a royalty
of two percent (2% ) of NET SALES by LICENSEE and sublicensees. Should LICENSEE
be required to pay running royalties to a third party on any patent rights not
licensed hereunder ("Other Royalties") in order to make, use, import or sell a
particular LICENSED PRODUCT or LICENSED PROCESS, LICENSEE shall be entitled to
credit half (50%) of such Other Royalties against the running royalty due,
provided that the running royalties shall not be reduced below fifty percent
(50%) of those that would otherwise be due UNEMED for that LICENSED PRODUCT or
LICENSED PROCESS. In the case of sublicenses, LICENSEE shall also pay to UNEMED
a royalty of fifty percent (50%) of NON-ROYALTY SUBLICENSE INCOME, provided that
the sublicense grant is solely for PATENT RIGHTS and grants no additional rights
(including but not limited to patent, tangible property, know-how, data,
trademarks) to the sublicense which are owned or controlled by LICENSEE. Such
consideration shall include any upfront, annual, milestone or other payments and
value above fair market value of any equity purchased by sublicensee.
Consideration shall not include any research or development money paid to
LICENSEE to conduct research in the FIELD pursuant to a research plan and
budget.

Only one royalty shall be due under this Agreement for any given LICENSED
PRODUCT or LICENSED PROCESS if covered by multiple patents under PATENT RIGHTS.

Payment of royalty for any given LICENSED PRODUCT or LICENSED PROCESS does not
require either determination of infringement or validity of PATENT RIGHTS prior
to being paid to UNEMED, but rather on presumption of validity. Any royalties
already paid to UNEMED are nonrefundable should a court of competent
jurisdiction render a determination of invalidity of PATENT RIGHTS.

     (b) If the license pursuant to this Agreement is converted to a
non-exclusive one and if other non-exclusive licenses in the same FIELD and
TERRITORY are granted, the above royalties shall not exceed the royalty rate to
be paid by other licensees in the same FIELD and TERRITORY during the term of
the non-exclusive license.

     (c) On sales between LICENSEE and its AFFILIATES or sublicensees for
resale, the royalty shall be paid on the NET SALES of the AFFILIATE or
sublicensee.

4.3 No later than January 1 of the third calendar year after the effective date
of this Agreement,

<PAGE>

as provided below, LICENSEE shall pay to UNEMED the following non-refundable
license maintenance royalty and/or advance on royalties. Such payments may be
credited against running royalties due for that calendar year and Royalty
Reports shall reflect such a credit. Such payments shall not be credited against
milestone payments (if any) or against royalties due for any subsequent calendar
year.

<TABLE>
<S>                     <C>
January 1, 2006,        $3,000
January 1, 2007 ,       $3,000
January 1, 2008,        $4,000
each year thereafter,   $7,000
</TABLE>

                                    ARTICLE V

                                    REPORTING

5.1 Prior to signing this Agreement, LICENSEE has provided to UNEMED a written
research and development plan under which LICENSEE intends to bring the subject
matter of the licenses granted hereunder into commercial use upon execution of
this Agreement. Such plan includes projections of sales, proposed marketing
efforts and the plan for achieving milestones outlined in Article III, Section
3.2 (c) (i) - (iii). A copy of this plan is included in Appendix A of this
agreement.

5.2 No later than sixty (60) days after June 30 of each calendar year, LICENSEE
shall provide to UNEMED a written annual progress report describing progress on
research and development, regulatory approvals, manufacturing, sublicensing,
marketing and sales during the most recent twelve (12) month period ending June
30 and plans for the forthcoming year. If multiple technologies are covered by
the license granted hereunder, the progress report shall provide the information
set forth above for each technology. If progress differs from that anticipated
in the plan required under

Paragraph 5.1, LICENSEE shall explain the reasons for the difference and propose
a modified research and development plan for UNEMED's review and approval.
LICENSEE shall also provide any reasonable additional information UNEMED
reasonably request to evaluate LICENSEE's performance.

5.3 LICENSEE shall report to UNEMED the date of first sale of LICENSED PRODUCTS
(or results of LICENSED PROCESSES) in each country within sixty (60) days of
occurrence.

5.4 (a) Upon commencing sales of LICENSED PRODUCTS or LICENSED PROCESSES as
described in 5.3, LICENSEE shall thereafter submit to UNEMED within sixty (60)
days after each calendar half year ending June 30 and December 31, a Royalty
Report setting forth for such half year at least the following information:

<PAGE>

          (i) the number of LICENSED PRODUCTS sold by LICENSEE, its AFFILIATES
          and sublicensees in each country;

          (ii) total billings for such LICENSED PRODUCTS;

          (iii) an accounting for all LICENSED PROCESSES used or sold;

          (iv) deductions applicable to determine the NET SALES thereof;

          (v) the amount of NON-ROYALTY SUBLICENSE INCOME received by LICENSEE;
          and

          (vi) the amount of royalty due thereon, or, if no royalties are due to
          UNEMED for any reporting period, the statement that no royalties are
          due.

          Such report shall be certified as correct by an officer of LICENSEE
and shall include a detailed listing of all deductions from royalties.

     (b) LICENSEE shall pay to UNEMED with each such Royalty Report the amount
of royalty due with respect to such half year. LICENSEE shall specify, by Patent
number, which PATENT RIGHTS are utilized for each LICENSED PRODUCT and LICENSED
PROCESS included in the Royalty Report.

     (c) All payments due hereunder shall be deemed received when funds are
credited to UNEMED's bank account and shall be payable by check or wire transfer
in United States dollars. Conversion of foreign currency to U.S. dollars shall
be made at the conversion rate existing in the United States (as reported in the
New York Times or the Wall Street Journal) on the last working day of each
royalty period. No transfer, exchange, collection or other charges shall be
deducted from such payments.

     (d) All such reports and sublicenses provided to UNEMED by LICENSEE shall
be maintained in confidence by UNEMED except as required by law; however, UNEMED
may include in its usual reports annual amounts of royalties paid.

     (e) Late payments shall be subject to a charge of one and one half percent
(1 1/2%) per month.

5.5 In the event of acquisition, merger, change of corporate name, or change of
make- up, organization, or identity, LICENSEE shall notify UNEMED in writing
within thirty (30) days of such event.

5.6 If LICENSEE or any AFFILIATE or sublicensee (or optionee) does not qualify
as a "small

<PAGE>

entity" as provided by the United States Patent and Trademark Office, LICENSEE
must notify UNEMED immediately.

                                   ARTICLE VI

                                 RECORD KEEPING

6.1 LICENSEE shall keep, and shall require its AFFILIATES and sublicensees to
keep, accurate records (together with supporting documentation) of LICENSED
PRODUCTS made, used or sold under this Agreement, appropriate to determine the
amount of royalties due to UNEMED hereunder. Such records shall be retained for
at least three (3) years following the end of the reporting period to which they
relate. They shall be available during normal business hours for examination by
an accountant of nationally recognized stature selected by UNEMED and reasonably
acceptable to LICENSEE, for the sole purpose of verifying reports and payments
hereunder. UNEMED shall provide Company five (5) business days notice in writing
prior to examination. In conducting examinations pursuant to this paragraph,
UNEMED's accountant shall have access to all records, which UNEMED reasonably
believes to be relevant to the calculation of royalties under Article IV.

6.2 UNEMED's accountant shall not disclose to UNEMED any information other than
information relating to the accuracy of reports and payments made hereunder.

6.3 Such examination by UNEMED's accountant shall be at UNEMED's expense, except
that if such examination shows an underreporting or underpayment in excess of
five percent (5%) for any twelve (12) month period, then LICENSEE shall pay the
cost of such examination as well as any additional sum that would have been
payable to UNEMED had the LICENSEE reported correctly, plus interest on said sum
at the rate of one and one half per cent (1 1/2%) per month.

<PAGE>

                                   ARTICLE VII

               DOMESTIC AND FOREIGN PATENT FILING AND MAINTENANCE

7.1 Upon execution of this Agreement, LICENSEE shall assume responsibility for
and reimburse UNEMED for all reasonable expenses UNEMED incurs related to the
maintenance of issued patent # 6,197,345. LICENSEE shall reimburse UNEMED within
sixty (60) days of receiving an invoice for all such expenses upon receipt of
invoices from UNEMED. Late payment of these invoices shall be subject to
interest charges of one and one-half percent (1 1/2%) per month. In the event
UNEMED grants rights to issued patent # 6,197,345 for development in a different
FIELD, responsibility for maintenance fees will thereafter be assumed by
subsequent licensee. UNEMED shall, in its sole discretion, be responsible for
the preparation, filing, prosecution and maintenance of any and all patent
applications and patents included in PATENT RIGHTS. UNEMED shall consult with
LICENSEE as to the preparation, filing, prosecution and maintenance of such
patent applications and patents which are within the FIELD and shall furnish to
LICENSEE copies of documents relevant to any such preparation, filing,
prosecution or maintenance.

7.2 UNEMED and LICENSEE shall cooperate fully in the preparation, filing,
prosecution and maintenance of PATENT RIGHTS and of all patents and patent
applications licensed in the FIELD to LICENSEE hereunder, executing all papers
and instruments or requiring members of UNEMED to execute such papers and
instruments so as to enable UNEMED to apply for, to prosecute and to maintain
patent applications and patents in UNEMED's name in any country. Each party
shall provide to the other prompt notice as to all matters which come to its
attention and which may affect the preparation, filing, prosecution or
maintenance of any such patent applications or patents. In particular, LICENSEE
must immediately notify UNEMED if LICENSEE or any AFFILIATE or sublicensee (or
optionee) does not qualify as a "small entity" as provided by the United States
Patent and Trademark Office.

7.3 LICENSEE may elect to surrender its PATENT RIGHTS in any country upon sixty
(60) days written notice to UNEMED. Such notice shall not relieve LICENSEE from
responsibility to reimburse UNEMED for patent-related expenses owed by LICENSEE
pursuant to paragraph 7.1 incurred prior to the expiration of the (60)-day
notice period (or such longer period specified in LICENSEE's notice).

                                  ARTICLE VIII

                                  INFRINGEMENT

8.1 With respect to any PATENT RIGHTS that are exclusively licensed to LICENSEE
pursuant to this Agreement, LICENSEE shall have the right to prosecute in its
own name and at its own expense any infringement of such patent, so long as such
license is exclusive at the time of the commencement of such action. UNEMED
agrees to notify LICENSEE promptly of each

<PAGE>

infringement of such patents of which UNEMED is or becomes aware. Before
LICENSEE commences an action with respect to any infringement of such patents,
LICENSEE shall give careful consideration to the views of UNEMED and to
potential effects on the public interest in making its decision whether or not
to sue.

8.2 (a) If LICENSEE elects to commence an action as described above, UNEMED
and/or INSTITUTIONS may, to the extent permitted by law, elect or be required to
join as a party in that action. Regardless of whether UNEMED and/or INSTITUTIONS
elect to join as a party, UNEMED and/or INSTITUTIONS shall cooperate fully with
LICENSEE in connection with any such action.

     (b) If UNEMED and/or INSTITUTIONS elect to join as a party pursuant to
subparagraph (a), joining parties shall jointly control the action with
LICENSEE.

     (c) LICENSEE shall reimburse UNEMED and/or INSTITUTIONS for any
pre-approved, reasonable costs incurred by LICENSEE's attorney on behalf of
UNEMED and/or INSTITUTIONS, including reasonable attorneys' fees incurred, as
part of an action brought by LICENSEE, irrespective of whether UNEMED and/or
INSTITUTIONS become a co-plaintiff.

     (d) UNEMED and/or INSTITUTIONS may, at their own expense, engage separate
counsel for such infringement action.

8.3 If LICENSEE elects to commence an action as described above, LICENSEE may
deduct from its royalty payments to UNEMED with respect to the patent(s) subject
to suit an amount not exceeding fifty percent (50%) of LICENSEE's expenses and
costs of such action, including reasonable attorneys' fees; provided, which
shall be prorated to reflect expenses relating to licensed PATENT RIGHTS among
all patents involved in litigation. However, such reduction shall not exceed
seventy five percent (75%) of the total royalty due to UNEMED with respect to
the patent(s) subject to suit for each calendar year. If such fifty percent
(50%) of LICENSEE's expenses and costs exceeds the amount of royalties deducted
by LICENSEE for any calendar year, LICENSEE may to that extent reduce the
royalties due to UNEMED from LICENSEE in succeeding calendar years, but never by
more than seventy five percent (75%) of the total royalty due in any one year
with respect to the patent(s) subject to suit.

8.4 No settlement, consent judgment or other voluntary final disposition of the
suit may be entered into without the prior written consent of UNEMED, which
consent shall not be unreasonably withheld.

8.5 Recoveries or reimbursements from actions commenced pursuant to this Article
shall first be applied to reimburse LICENSEE and UNEMED and/or INSTITUTIONS for
litigation costs not paid from royalties and then to reimburse UNEMED for
royalties deducted by LICENSEE

<PAGE>

pursuant to paragraph 8.3. Any remaining recoveries or reimbursements shall be
shared with LICENSEE, receiving sixty percent (60%) and UNEMED receiving forty
percent (40%). Should additional patents other than PATENT RIGHTS be involved in
the infringement suit, any recoveries and reimbursements shall be prorated and
allocated equally among the patents involved in the litigation, with UNEMED
sharing in reimbursements based upon the prorated share of the PATENT RIGHTS.

8.6 If LICENSEE elects not to exercise its right to prosecute an infringement of
the PATENT RIGHTS pursuant to this Article, UNEMED and/or INSTITUTIONS may do so
at their own expense, controlling such action and retaining all recoveries there
from. LICENSEE shall cooperate fully with UNEMED and/or INSTITUTIONS in
connection with any such action, however, UNEMED and/or INSTITUTIONS shall pay
any reasonable costs incurred by LICENSEE. UNEMED shall consult with LICENSEE
and consider any reasonable reasons as to why LICENSEE elects not to pursue an
infringement suit.

8.7 Without limiting the generality of paragraph 8.6, UNEMED may, at its
election and by notice to LICENSEE, establish a time limit of three (3) months
for LICENSEE to decide whether to prosecute any infringement of which UNEMED is
or becomes aware. If, by the end of such three (3) month period, LICENSEE has
not commenced such an action, UNEMED and/or INSTITUTIONS may prosecute such an
infringement at their own expense, controlling such action and retaining all
recoveries there from. With respect to any such infringement action prosecuted
by UNEMED and/or INSTITUTIONS in good faith, LICENSEE shall pay over to UNEMED
any payments (whether or not designated as "royalties") made by the alleged
infringer to LICENSEE under any existing or future sublicense authorizing
LICENSED PRODUCTS, up to the amount of UNEMED's and/or INSTITUTIONS'
unreimbursed litigation expenses (including, but not limited to, reasonable
attorneys' fees).

8.8 If a declaratory judgment action is brought naming LICENSEE as a defendant
and alleging invalidity of any of the PATENT RIGHTS, UNEMED and/or INSTITUTIONS
may elect to take over the sole defense of the action at its own expense.
LICENSEE shall cooperate fully with UNEMED and/or INSTITUTIONS in connection
with any such action.

                                   ARTICLE IX

                            TERMINATION OF AGREEMENT

9.1 This Agreement, unless terminated as provided herein, shall remain in effect
until the last patent or patent application in PATENT RIGHTS has expired or been
finally abandoned without the possibility of revival, or held invalid by a court
of competent jurisdiction.

9.2 UNEMED may terminate this Agreement as follows:

<PAGE>

     (a) If LICENSEE does not make a payment due hereunder and fails to cure
such non-payment (including the payment of interest in accordance with paragraph
5.4(e)) within forty-five (45) days after the date of notice in writing of such
non-payment by UNEMED.

     (b) If LICENSEE defaults in its obligations under paragraph 10.4(c) and
10.4(d) to procure and maintain insurance after a forty-five (45) day cure
period.

     (c) If, at any time after three years from the date of this Agreement,
UNEMED determines that the Agreement should be terminated pursuant to paragraph
3.2(d).

     (d) If LICENSEE shall become insolvent, shall make an assignment for the
benefit of creditors, or shall have a petition in bankruptcy filed for or
against it and has not been dismissed within one hundred eighty (180) days. Such
termination shall be effective immediately upon UNEMED giving written notice to
LICENSEE.

     (e) If an examination by UNEMED's accountant pursuant to Article VI shows
an underreporting or underpayment by LICENSEE in excess of 20% for any twelve
(12) month period.

     (f) If LICENSEE is convicted of a felony relating to the manufacture, use,
or sale of LICENSED PRODUCTS.

     (g) Except as provided in subparagraphs (a), (b), (c), (d), (e) and (f)
above, if LICENSEE defaults in the performance of any obligations under this
Agreement and the default has not been remedied within ninety (90) days after
the date of notice in writing of such default by UNEMED.

9.3 LICENSEE shall provide, in all sublicenses granted by it under this
Agreement, that LICENSEE's interest in such sublicenses shall become direct
licensees of UNEMED.

9.4 LICENSEE may terminate this Agreement by giving ninety (90) days advance
written notice of termination to UNEMED . Upon termination, LICENSEE shall
submit a final Royalty Report to UNEMED and any royalty payments and
unreimbursed patent expenses invoiced by UNEMED shall become immediately
payable.

9.5 Paragraphs 6.1, 6.2, 6.3, 7.1, 8.5, 9.4, 9.5, 10.2, 10.3,10.4, 10.6, 10.7,
and 10.8 of this Agreement shall survive termination.

                                    ARTICLE X

                                     GENERAL

<PAGE>

10.1 UNEMED does not warrant the validity of the PATENT RIGHTS licensed
hereunder and makes no representations whatsoever with regard to the scope of
the licensed PATENT RIGHTS or that such PATENT RIGHTS may be exploited by
LICENSEE, an AFFILIATE, or sublicensee without infringing other patents.

10.2 EXCEPT AS EXPRESSLY SET FORTH HEREIN, BOTH PARTIES EXPRESSLY DISCLAIM ANY
AND ALL IMPLIED OR EXPRESS WARRANTIES AND UNEMED MAKES NO EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE
PATENT RIGHTS, OR INFORMATION SUPPLIED BY UNEMED, LICENSED PROCESSES OR LICENSED
PRODUCTS CONTEMPLATED BY THIS AGREEMENT.

10.3 (a) LICENSEE shall indemnify, defend and hold harmless UNEMED and
INSTITUTIONS, their Regents, current or former directors, governing board
members, trustees, officers, faculty, medical and professional staff, employees,
students, and agents and their respective successors, heirs and assigns
(collectively, the "INDEMNITEES"), from and against any third party claim,
proceeding, demand, liability, cost, expense, damage, deficiency, loss or
obligation of any kind or nature (including, without limitation, reasonable
attorney's fees and other costs and expenses of litigation) (collectively,
"Claims"), based upon, arising out of the transfer, production, manufacture,
sale, use, lease, consumption, or advertisement of products, processes or
materials licensed by this Agreement or any other liabilities or obligations
otherwise relating to this Agreement, including without limitation any cause of
action relating to product liability concerning any product, process, or service
made, used or sold pursuant to any right or license granted under this
Agreement.

     (b) LICENSEE shall, at its own expense, provide attorneys reasonably
acceptable to UNEMED to defend against any actions brought or filed against any
Indemnitee hereunder with respect to the subject of indemnity contained herein,
whether or not such actions are rightfully brought.

     (c) Beginning at the time any such product, process or service is being
commercially distributed or sold (other than for the purpose of obtaining
regulatory approvals) by LICENSEE or by a sublicensee, AFFILIATE or agent of
LICENSEE, LICENSEE shall, at its sole cost and expense, procure and maintain
commercial general liability insurance in amounts not less than $2,000,000 per
incident and $2,000,000 annual aggregate and naming the Indemnitees as
additional insureds. During clinical trials of any such product, process or
service, LICENSEE shall, at its sole cost and expense, procure and maintain
commercial general liability insurance in such equal or lesser amount as UNEMED
shall require, naming the Indemnitees as additional insureds. Such commercial
general liability insurance shall provide (i) product liability coverage and
(ii) broad form contractual liability coverage for LICENSEE's indemnification
under this Agreement. If LICENSEE elects to self-insure all or part of the
limits described above (including deductibles or retentions which are in excess
of $250,000 annual aggregate) such self-

<PAGE>

insurance program must be acceptable to UNEMED in its sole discretion. The
minimum amounts of insurance coverage required shall not be construed to create
a limit of LICENSEE's liability with respect to its indemnification under this
Agreement.

     (d) LICENSEE shall provide UNEMED with written evidence of such insurance
upon request of UNEMED. LICENSEE shall provide UNEMED with written notice at
least fifteen (15) days prior to the cancellation, non-renewal or material
change in such insurance; if LICENSEE does not obtain replacement insurance
providing comparable coverage within such fifteen (15) day period, UNEMED shall
have the right to terminate this Agreement effective at the end of such fifteen
(15) day period without notice or any additional waiting periods.

     (e) LICENSEE shall maintain such commercial general liability insurance
beyond the expiration or termination of this Agreement during (i) the period
that any product, process, or service, relating to, or developed pursuant to,
this Agreement is being commercially distributed or sold by LICENSEE or by a
sublicensee, AFFILIATE or agent of LICENSEE and (ii) a reasonable period after
the period referred to in (e)(i) above which in no event shall be less than
fifteen (15) years.

10.4 LICENSEE shall not use name or insignia of UNEMED or INSTITUTIONS or any
adaptation of them, or the name of any of inventors in any advertising,
promotional or sales literature without the prior written approval of UNEMED.
Likewise, UNEMED or INSTITUTIONS shall not use the name or any adaptation of the
name of LICENSEE in any advertising, promotional or sales literature without
prior written approval of LICENSEE. Each party shall provide written approval or
denial within five (5) business days of such request.

10.5 Without the prior written approval of UNEMED in each instance, neither this
agreement nor the rights granted hereunder shall be transferred or assigned in
whole or in part by LICENSEE to any person whether voluntarily or involuntarily,
by operation of law or otherwise, except that the LICENSEE shall have the right
to assign this Agreement to another party without the consent of UNEMED in the
case of the sale, merger, change of control or transfer by LICENSEE of all, or
substantially all, of its assets relating to the LICENSED PRODUCT or LICENSED
PROCESS, to that party. This Agreement shall be binding upon the respective
successors, legal representatives and assignees of UNEMED and LICENSEE.

10.6 The interpretation and application of the provisions of this Agreement
shall be governed by the laws of the State of Nebraska.

10.7 LICENSEE shall comply with all applicable laws and regulations. In
particular, it is understood and acknowledged that the transfer of certain
commodities and technical data is subject to United States laws and regulations
controlling the export of such commodities and technical data, including all
Export Administration Regulations of the United States Department of Commerce.
These laws and regulations among other things, prohibit or require a license for
the export of certain types of technical data to certain specified countries.
LICENSEE hereby

<PAGE>

agrees and gives written assurance that it will comply with all United States
laws and regulations controlling the export of commodities and technical data,
that it will be solely responsible for any violation of such by LICENSEE or its
AFFILIATES or sublicensees, and that it will defend and hold UNEMED and
INSTITUTIONS harmless in the event of any legal action by a third party of any
nature occasioned by such violation.

10.8 LICENSEE agrees (i) to use commercially reasonable efforts to obtain all
regulatory approvals required for the manufacture and sale of LICENSED PRODUCTS
and LICENSED PROCESSES and (ii) to utilize appropriate patent marking on such
LICENSED PRODUCTS. LICENSEE also agrees to use commercially reasonable efforts
to register or record this Agreement as is required by law or regulation in any
country where the license is in effect.

10.9 Except as expressly set forth in this Agreement, nothing contained herein
shall be construed as a grant of a license in, to or regarding any materials,
information, technology, patent rights or other intellectual property rights of
LICENSEE or INSTITUTIONS.

10.10 Any notices to be given hereunder shall be sufficient if signed by the
party (or Party's attorney) giving it and either

(a)  delivered in person, or (b) mailed certified mail return receipt requested,
     or (c) faxed to other party if the sender has evidence of successful
     transmission and if the sender promptly sends the original by ordinary
     mail, in any event to the following addresses:

               If to LICENSEE:

                    ImaRx Therapeutics, Inc.
                    1635 E. 18th Street
                    Tucson, AZ 85719
                    Tel. 520-770-1259
                    Fax. 520-791-2437

               If to UNEMED:

                    UNEMED Corporation
                    986099 Nebraska Medical Center
                    Omaha, Nebraska, U.S. 69198-6099
                    Telephone Number 402-559-2468
                    Fax Number 402-559-2182

     By such notice either party may change their address for future notices.

     Notices delivered in person shall be deemed given on the date delivered.
Notices sent by fax shall be deemed given on the date faxed. Notices mailed
shall be deemed given on the date postmarked on the envelope.

10.11 Should a court of competent jurisdiction later hold any provision of this
Agreement to be

<PAGE>

invalid, illegal, or unenforceable, and such holding is not reversed on appeal,
it shall be considered severed from this Agreement. All other provisions, rights
and obligations shall continue without regard to the severed provision, provided
that the remaining provisions of this Agreement are in accordance with the
intention of the parties.

10.12 In the event of any controversy or claim arising out of or relating to any
provision of this Agreement or the breach thereof, the parties shall try to
settle such conflict amicably between themselves. This may include mediation,
arbitration, or any other procedures upon which the parties agree. Each party
agrees that, prior to resorting to litigation to resolve any dispute, it will
confer with other party to determine whether other procedures that are less
expensive or less time consuming can be adopted to resolve the dispute. Such
means of conflict resolution procedures shall be held in Omaha, Nebraska.
Notwithstanding the foregoing, either party may, without recourse to the above
mentioned conflict resolution procedure, assert against the other party a
third-party claim or cross-claim in any action brought by a third party, to
which the subject matter of this Agreement may be relevant.

10.13 This Agreement constitutes the entire understanding between the parties
and neither party shall be obligated by any condition or representation other
than those expressly stated herein or as may be subsequently agreed to by the
parties hereto in writing.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
by their duly authorized representatives.

UNEMED CORPORATION                      IMARX THERAPEUTICS, INC.:

Thomas L. McDonald , Ph.D. President    Name: Jean Carlyle, CPA, MPA CFO

/s/ Thomas McDonald                     /s/ Jean Carlyle
-------------------------------------   ----------------------------------------
Signature                               Signature

Date 10-28-03                           Date 10-21-03<PAGE>
                                                                   EXHIBIT 10.11

                  ASSIGNMENT, ASSUMPTION AND LICENSE AGREEMENT

         ASSIGNMENT, ASSUMPTION AND LICENSE AGREEMENT dated as of October 7,
1999 (the "Agreement") by and between IMARX, LLC, an Arizona limited liability
company ("Purchaser") and IMARX PHARMACEUTICAL CORP., an Arizona corporation
("Seller"). Capitalized terms used but not otherwise defined herein have the
meanings assigned to them in the Technology Agreements (as defined below).

                                    RECITALS

         A. Seller is engaged in the research and development of pharmaceutical
products. Among other assets, Seller owns certain patents and patent
applications in the field of ultrasound diagnostic imaging. Seller has
previously assigned and/or licensed certain of its patents and patent
applications to DuPont Pharmaceuticals Company ("DuPont") pursuant to the
Assignment and License Agreement dated October 23, 1995 and the License and
Marketing Agreement dated October 23, 1995, and amendments thereto (hereinafter
collectively referred to as the "Technology Agreements").

         B. DuPont has made an offer to acquire the stock of Seller, provided
that Seller divests itself of certain assets and liabilities. The parties
anticipate that Seller will be merged into a subsidiary of DuPont (the "Merger")
pursuant to an Agreement and Plan of Merger (the "Acquisition Agreement").

         C. Purchaser will assume all liabilities of Seller other than those
liabilities specifically retained by Seller and accepted by DuPont in the
Acquisition Agreement (the "Assumed Liabilities"). Purchaser wishes to acquire
certain assets of Seller (including the "Physical Assets and Receivables" and
the "Category III Assets") identified on Exhibit A. Seller wishes to license the
Category III Assets back from Purchaser for use within the field of contrast
enhancement of diagnostic ultrasound imaging, but specifically excluding
targeted and tissue specific diagnostic ultrasound products. This field of use
is referred to herein as "CEDUI."

         D. Purchaser wishes to license from Seller certain assets to be
acquired by DuPont in connection with the Acquisition Agreement (the "Category
II Assets") identified on Exhibit B for use outside of CEDUI.

         E. Seller wishes to secure from Purchaser a right of first negotiation
with respect to new products developed by Purchaser in the fields of thrombus
imaging and sonothrombolysis.

         F. The parties wish to agree on certain procedures and responsibilities
for addressing certain claims of infringement that may arise from Seller's
practice of its technology.

         G. The execution and delivery of this Agreement by Purchaser is a
condition to the obligations of Seller to consummate the transactions
contemplated by the Acquisition Agreement.

<PAGE>

                                    AGREEMENT

         NOW, THEREFORE, in consideration of the foregoing premises and of the
agreements and covenants set forth in the Acquisition Agreement, Purchaser and
Seller agree as follows:

1.       Assignment of Assets.

         a.       Seller hereby grants, conveys, sells, transfers and assigns to
                  Purchaser, free and clear of all debts, obligations, liens and
                  encumbrances (other than the Assumed Liabilities, as that term
                  is defined below) all of the assets described on Exhibit A
                  hereto; provided, however, that the Category III Assets shall
                  not include any Assets to be acquired by DuPont in the Merger.

         b.       Seller hereby assigns to Purchaser its rights under the
                  Assigned Patents, as that term is defined in the Technology
                  Agreements, which rights are fully set forth and described in
                  Section 3 of the Assignment and License Agreement dated
                  October 23, 1995. Purchaser's license rights granted therein
                  will survive any termination, cancellation, or modification of
                  the Assignment and License Agreement by Seller.

2.       Assignment of Name. Effective as of the date of Closing pursuant to the
         Acquisition Agreement, Seller hereby assigns the name "ImaRx
         Pharmaceuticals" along with any variations thereof to Purchaser along
         with the goodwill associated with the Category III Assets. Seller will
         execute any additional documents necessary to transfer the name to
         Purchaser.

3.       Assumption of Liabilities. Seller hereby assigns to Purchaser, and
         Purchaser hereby assumes and agrees to pay, perform and discharge, and
         to indemnify Seller against and hold it harmless from all of the
         liabilities and obligations of Seller accrued or arising before the
         Closing (as that term is described in the Acquisition Agreement),
         including without limitation those Liabilities set forth on Exhibit D
         hereto (the "Assumed Liabilities"); provided, however, that the Assumed
         Liabilities shall not include any liabilities or obligations to be
         assumed by DuPont in the Merger as provided in the Acquisition
         Agreement.

4.       License by Seller. Seller hereby grants to Purchaser an exclusive,
         transferable license to the Category II Assets, with right to
         sublicense, to make, have made, import, use, and sell product derived
         from the Category II Assets, worldwide, for every field of use outside
         of CEDUI. Seller also grants to Purchaser the right to file and
         prosecute divisional applications for patent claims relating solely to
         fields of use outside of CEDUI arising from patent applications
         included within Category II Assets, provided that Purchaser will be
         solely responsible for all costs and expenses incurred in connection
         with such filing and prosecution and further provided that Purchaser
         will have no right to practice, transfer, license, or otherwise exploit
         any patents issuing from such applications within CEDUI. Seller
         expressly retains all rights to the Category II Assets within CEDUI,
         including, without limitation, all rights relating to the product
         Definity(R), all related products (including, without limitation,
         MRX-421A1 and MRX-132), all back-up products, next-generation products,
         and improvements thereto.

                                       2
<PAGE>

5.       License by Purchaser. Upon assignment of the Category III Assets,
         Purchaser grants to Seller an exclusive, transferable license to the
         Category III Assets, with right to sublicense, to make, have made,
         import, use, and sell products derived from the Category III Assets,
         worldwide, within CEDUI. Purchaser expressly retains all rights to the
         Category III Assets outside CEDUI.

6.       Seller's Right of First Negotiation to Purchaser's Products. If
         Purchaser develops products or technology in the area of thrombus
         imaging or sonothrombolysis, (collectively, "New Product"), Purchaser
         will offer to Seller an exclusive license to the New Product for
         development and commercialization before offering the New Product to
         any third party for license. In connection therewith, Purchaser will
         provide Seller with all relevant information requested by Seller and
         reasonably available to Purchaser concerning the New Product. Seller
         will then have ninety (90) days within which to make an offer for the
         New Product. If Seller makes such an offer, the parties will negotiate
         promptly and in good faith to arrive at an agreement. If the parties
         fail to reach such an agreement within a reasonable period, Purchaser
         may assign, license, or otherwise transfer rights in the New Product to
         a third party, but only on terms that are, on balance, not less
         favorable to Purchaser than the last written offer of Seller, as
         reasonably determined by Purchaser, or may pursue commercial
         development of the New Product on its own, at Purchaser's election.

7.       Representations and Warranties.

         a.       By Seller. Seller represents and warrants as follows:

                  (i)      Seller is the sole owner of the Category II Assets
                           and Category III Assets and, subject to any limited
                           rights that the U.S. government might have, has the
                           legal authority to assign the Category III Assets and
                           to license the Category II Assets to Purchaser and
                           otherwise to enter into and perform all of its
                           obligations set forth herein;

                  (ii)     all corporate and other formalities necessary to
                           authorize execution, delivery and performance of this
                           Agreement (and all other documents executed and
                           delivered in connection herewith) on behalf of Seller
                           have been taken; and

         Seller makes no other warranties, express or implied, except as
expressly set forth in this Agreement. In particular, and without limitation,
Seller makes no implied or express warranties of noninfringement or validity or
any other representation or warranty whatsoever regarding Patents or Product.

         b.       By Purchaser. Purchaser represents and warrants as follows:

                  (i)      Purchaser has the legal authority to accept the
                           assignment of Category III Assets and the license to
                           Category II Assets granted hereunder and otherwise to
                           perform all of its obligations set forth herein;

                                       3
<PAGE>

                  (ii)     all LLC and other formalities necessary to authorize
                           execution, delivery and performance of this Agreement
                           (and all other documents executed and delivered in
                           connection herewith) on behalf of Purchaser have been
                           taken.

Purchaser makes no other warranties, express or implied, except as expressly set
forth in this Agreement. In particular, and without limitation, Purchaser makes
no implied or express warranties of noninfringement or validity or any other
representation or warranty whatsoever regarding Patents or Product.

8.       Intellectual Property Protection.

         a.       Claim of Infringement. If Purchaser discovers that a third
                  party claims that practice of the Category II Assets infringes
                  a patent or other intellectual property right of such third
                  party, then Purchaser will promptly so notify Seller and
                  Seller shall have sole authority to defend against or settle
                  any such claim of infringement, provided that no settlement
                  will impair Purchaser's license granted by Section 4 above. If
                  Seller discovers that a third party claims that practice of
                  the Category III Assets infringes a patent or other
                  intellectual property right of such third party, then Seller
                  will promptly so notify Purchaser and Purchaser shall have
                  sole authority to defend against or settle any such claim of
                  infringement, provided that no settlement will impair Seller's
                  license granted by Section 5 above.

         b.       Infringement of Patents. If either party becomes aware that a
                  third party is or may be infringing the Patents, it shall
                  promptly so notify the other party. If the infringement
                  related to Category II Assets, Seller shall have authority to
                  pursue a claim for infringement. If Seller fails to resolve
                  such infringement or institute an infringement action against
                  the third party within one hundred twenty (120) days after
                  Seller becomes aware of the infringement, Seller will assign
                  its rights to pursue the infringement to Purchaser. If there
                  is infringement related to Category III Assets, Purchaser
                  shall have authority to pursue a claim for infringement. If
                  Purchaser fails to resolve such infringement or institute an
                  infringement action against the third party within one hundred
                  twenty (120) days after Purchaser becomes aware of the
                  infringement, then Purchaser shall assign its rights to pursue
                  the infringement to Seller.

9.       Claim of Infringement of Sonus Patents. Notwithstanding anything to the
         contrary contained in Section 8 above, the provisions of this Section 9
         will apply to and govern any claim asserted (whether by litigation or
         otherwise) by Sonus Pharmaceuticals, Inc. and/or its licensees or
         assignees (collectively, "Sonus") within five years of the date of this
         Agreement that Seller's manufacture or sale of the product known as
         Definity(R) infringes a patent or other intellectual property right of
         Sonus (a "Sonus infringement claim"). If Seller receives a Sonus
         infringement claim, it will promptly so notify Purchaser, and the
         parties will proceed as follows:

                                       4
<PAGE>

         a.       Seller will keep Purchaser informed of developments relevant
                  to the Sonus claim and will consider Purchaser's
                  recommendations for proceeding, although Seller will have the
                  final authority;

         b.       Seller will use all commercially reasonable efforts to defeat
                  or resolve a Sonus claim, including but not limited to cross
                  licensing its diagnostic technology to Sonus;

         c.       Purchaser will use all commercially reasonable efforts in
                  cooperation with Seller and in support of Seller's efforts,
                  including the commitment of all reasonable amounts of Dr. Evan
                  Unger's time, subject to reimbursement by Seller of
                  Purchaser's out of pocket costs (which will not include the
                  value of Dr. Unger's time);

         d.       At Seller's election, if these commercially reasonable efforts
                  fail to resolve the Sonus claim and Seller believes it is at
                  substantial risk of losing the ability to manufacture or sell
                  Definity(R) in a commercially significant geographic market,
                  Purchaser will grant to Seller a transferable covenant not to
                  sue Sonus for infringement of Purchaser's Category III assets
                  to the extent necessary to allow Sonus to manufacture and sell
                  its therapeutic products, provided that Seller receives a
                  reciprocal covenant from Sonus, which Seller will then
                  transfer to Purchaser;

         e.       The covenant referenced in Paragraph 9.d above will be drawn
                  as narrowly as possible to allow Sonus to manufacture and sell
                  Sonus's therapeutic products, and will not be construed as a
                  license to allow Sonus to manufacture or sell products
                  developed by Purchaser or to grant Sonus and rights in any
                  safety or efficacy data developed by Purchaser relating to
                  those products; and

         f.       If Seller directs Purchaser to provide a covenant pursuant to
                  Paragraph 9.d, Seller will pay Purchaser the sum of $1.5
                  million in partial compensation for Purchaser's delivery of
                  the covenant.

10.      Indemnification.

         a.       Seller shall indemnify, defend, and hold Purchaser harmless
                  from any and all claims, demands, lawsuits, and associated
                  costs and expenses, including reasonable attorneys' fees and
                  cost of settlement, arising out of Seller's manufacture,
                  promotion, marketing, and sale of products derived from or
                  based on Category III Assets; provided, however, that Seller
                  shall not be obligated to indemnify, defend, and hold
                  Purchaser harmless where the claim, demand, lawsuit, and
                  associated costs and expenses, including reasonable attorneys'
                  fees and cost of settlement arises out of the breach of this
                  Agreement by Purchaser and further provided that Purchaser
                  promptly notifies Seller upon becoming aware of any such
                  claims. Seller shall have the right to conduct the defense of
                  any such claim but if Seller fails after reasonable notice
                  from Purchaser to conduct such defense, Purchaser shall have
                  the right to do so and Seller will reimburse

                                       5
<PAGE>

                  Purchaser for all reasonable costs and expenses of defending
                  the action, including attorneys' fees and costs of settlement.

         b.       Purchaser shall indemnify, defend, and hold Seller harmless
                  from any and all claims, demands, lawsuits, and associated
                  costs and expenses, including reasonable attorneys' fees and
                  cost of settlement, arising out of Purchaser's manufacture,
                  promotion, marketing, and sale of products derived from or
                  based on Category II Assets; provided however, that Purchaser
                  shall not be obligated to indemnify, defend, and hold Seller
                  harmless where the claim, demand, lawsuit, and associated
                  costs and expenses, including reasonable attorneys' fees and
                  cost of settlement arises out of the breach of this Agreement
                  by Seller and further provided that Seller promptly notifies
                  Purchaser upon becoming aware of any such claims. Purchaser
                  shall have the right to conduct the defense of any such claim
                  but if Purchaser fails after reasonable notice from Seller to
                  conduct such defense, Seller shall have the right to do so and
                  Purchaser will reimburse Seller for all reasonable costs and
                  expenses of defending the action, including attorneys' fees
                  and costs of settlement.

11.      Rights to Improvements in Product or Manufacturing. All assignments and
         licenses hereunder include such rights to improvements as Seller has
         received or is entitled to receive from DuPont pursuant to Section 5 of
         the Assignment and License Agreement dated October 23, 1995, through
         the date of the Closing of the Acquisition Agreement, to the extent
         that such improvements apply outside the field of CEDUI.

12.      Maintenance and Prosecution of Patents

         a.       Seller may elect not to prosecute or maintain a patent within
                  the Category II Assets if it reasonably concludes that such
                  patent has no significant value to Seller within the field of
                  CEDUI. In that event, it will so notify Purchaser. Purchaser
                  will, within ninety (90) days of receipt of such notice,
                  notify Seller whether it wishes to acquire the patent from
                  Seller. During this ninety (90) day period, Seller will take
                  any action necessary to continue to prosecute or maintain the
                  patent. Purchaser will reimburse Seller for its out-of-pocket
                  costs incurred in such actions. Upon notice by Purchaser that
                  it wishes to acquire the patent from Seller, Seller will
                  assign the patent to Purchaser, transfer any files or other
                  documents relating to the patent to Purchaser, and Purchaser
                  will thereafter be solely responsible for prosecution or
                  maintenance of the Patent, including all costs associated
                  therewith. Seller agrees to execute any additional documents
                  necessary to perfect Purchaser's rights to the patent.
                  Purchaser agrees that,

                                       6
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the day and year first above written.

<TABLE>
<CAPTION>
<S>                                                          <C>
IMARX PHARMACEUTICAL CORP.,                                  IMARX LLC,
an Arizona corporation                                       an Arizona limited liability company
By:  /s/ Evan Unger                                          By:     /s/ Evan Unger
     -------------------------------------                        -------------------------------------
Dr. Evan Unger                                               Dr. Evan Unger
Its:    President                                            Its:    Manager
     -------------------------------------                        -------------------------------------
</TABLE>

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}]]